MDM2 oncogene as a target for cancer therapy: An antisense approach.

International journal of oncology

Volumn 15, Issue 4, 1999, Pages 653-660

  Wang, H ^a   Zeng, X ^a   Oliver, P ^a   Le, L P ^a   Chen, J ^a   Chen, L ^a   Zhou, W ^a   Agrawal, S ^a   Zhang, R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CAMPTOTHECIN; DOXORUBICIN; DRUG DERIVATIVE; HOMOCAMPTOTHECIN; MDM2 PROTEIN, HUMAN; MDM2 PROTEIN, MOUSE; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2;

ANIMAL; ARTICLE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; CHORIOCARCINOMA; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENETICS; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; OSTEOSARCOMA; PATHOLOGY; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL DIVISION; CHORIOCARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL RATE; TUMOR CELLS, CULTURED;

MLCS; MLOWN;

EID: 0033210893     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.15.4.653     Document Type: Article

References (0)